Trial Profile
Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms AURA2
- Sponsors AstraZeneca; AstraZeneca AB
- 20 Feb 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 01 Dec 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.
- 05 Feb 2021 Planned End Date changed from 30 Dec 2020 to 31 Dec 2021.